Jeffrey Bashara

Experience

• Represented Pfizer, in its US$2.2 billion acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company, and in its US$11.6 billion acquisition of and spinoff transaction with Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
• Represented HP in its US$3.3 billion acquisition of Poly, a leading global provider of workplace collaboration solutions.
• Represented Becton Dickinson in its acquisition of Venclose, a provider of solutions for the treatment of chronic venous insufficiency.
• Represented a prominent orthopedics company in its acquisition of CrossRoads Extremity Systems, a developer of procedure-specific, sterile-packed implants and instruments for foot and ankle surgery.
• Represented National Financial Partners in its acquisition of Private Ocean, a leading fiduciary wealth management firm.
• Represented Altimeter Growth Corporation in its US$40 billion merger with Grab Holdings, Southeast Asia’s leading super-app for ride-hailing, deliveries, and financial services.
• Represented Ginkgo Bioworks in its acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform.
• Represented Preventice Solutions in its US$925 million sale to Boston Scientific.*
• Represented IXL Learning in its acquisition of Rosetta Stone’s languages division.*

*Asterisks indicate experience prior to joining Ropes & Gray.